intravitreal injection of ranibizumab

Phase 2Monoclonal antibody

intravitreal injection of ranibizumab is one of 89 small molecule programs targeting Choroidal Neovascularization. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Choroidal NeovascularizationActive, not recruiting

Retinopathy of PrematurityActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Diabetic RetinopathyActive, not recruiting

Choroidal NeovascularizationPhase 2/Phase 3

Active, not recruiting

Retinopathy of PrematurityPreclinical

Active, not recruiting

Diabetic Macular EdemaPhase 2

Active, not recruiting

Diabetic RetinopathyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

180 competitors in Diabetic Macular Edema

#DrugCompanyPhaseTrials

Eylea

Regeneron

Phase 3

54 2

Lucentis

Roche

Phase 3

59 3

Avastin

BBio-Thera Solutions

Phase 3

23 4

Beovu

Novartis

Phase 3

6 5

Kenalog

BBausch Health Americas, Inc.

Phase 3

14 6

Synalar

EEurofarma Laboratorios S.A.

Phase 3

4 7

Lucentis

Novartis

Phase 3

8 8

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 3

3 9

Glucophage

EMD Serono

Phase 3

1 10

Intravitreal Ranibizumab

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Macular Edema1 trial

Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion

Completed·RRetina Associates of Florida, P.A.·Phase 2·NCT00815360·22 enrolled

Diabetic Retinopathy1 trial

Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)

Unknown status·UUniversity of Sao Paulo·Phase 1/2·NCT00993525·22 enrolled

Recurrent1 trial

Intravitreal Ranibizumab in Recurrent ROP

Completed·AAmeera Gamal Abdelhameed··NCT04539106·115 enrolled

Macular Edema1 trial

Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

Completed·BBarnes Retina Institute·N/A·NCT01428388·150 enrolled

Retinopathy of Prematurity1 trial

Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease

Completed·KKantonsspital Aarau·N/A·NCT02164604·6 enrolled

1 more indication

Choroidal Neovascularization1 trial

Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization

Withdrawn·AAsociación para Evitar la Ceguera en México·Phase 2/3·NCT00930189

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for intravitreal injection of ranibizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intravitreal injection of ranibizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intravitreal injection of ranibizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Sao Paulo

intravitreal injection of ranibizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Macular Edema1 trial

Diabetic Retinopathy1 trial

Recurrent1 trial

Macular Edema1 trial

Retinopathy of Prematurity1 trial

Choroidal Neovascularization1 trial

References

Drug Info

Quick Facts

Related News